Does amitriptyline reduce pain in knee osteoarthritis?
Does low dose amitriptyline reduce pain in knee osteoarthritis? A double blind, randomised, pragmatic, placebo controlled clinical trial of amitriptyline compared to active placebo in addition to usual care
Monash University
160 participants
Jul 7, 2015
Interventional
Conditions
Summary
Knee osteoarthritis is one of the most common forms of arthritis. Pain, the main symptom, is poorly controlled by current treatment strategies. Pain is thought initially to originate from structural changes in an affected joint. However, after a while, in some people, changes occur in the nervous system that perpetuate the pain. These changes are referred to as pain sensitisation. They are not addressed by current treatments. Amitriptyline is commonly used to treat pain related to pain sensitisation, such as in shingles or diabetic neuropathy. This study is a randomised controlled trial of the use of amitriptyline, in addition to usual care, to manage pain in people with painful knee osteoarthritis. People with knee osteoarthritis will be randomised to receiving low dose amitriptyline or a placebo with many of the same side effects of the active drug, benztropine. They will be followed for 12 weeks to determine the effect of amitriptyline on pain, function and other symptoms of knee osteoarthritis.
Eligibility
Inclusion Criteria3
- Males and females with symptomatic knee OA for at least 3 months, defined by the ACR clinical and radiographic criteria (ie pain and radiographic OA) (Altman, R., et al., Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. . Arthritis Rheum, 1986. 29(8): p. 1039-49.)
- Pain score of at least 30 mm on a 100 mm visual analogue scale (VAS);
- Age > 40 years, and < 75 years old
Exclusion Criteria8
- Inability to give informed consent;
- Intra articular therapy over the past 3 months; Planning knee injection or surgical intervention in the next 4 months
- Patients with rheumatoid arthritis, other inflammatory arthritis, or significant knee injury;
- Patients with major depressive disorder for whom anti-depressant therapy is indicated
- Patients taking medications that are contra-indicated when taking amitriptyline (monoamine oxidase inhibitors, other antidepressants, opioids, drugs that inhibit CYP3A4, etc)
- Co-morbidity that may limit participation (e.g. any planned joint replacement in the next 4 months, medical conditions e.g. malignancy in the past 5 years other than non-melanoma skin cancer) or relocation;
- Fibromyalgia, as this is evidence of an alternative underlying explanatory condition
- Patients with contraindications to amitriptyline therapy eg acute angle glaucoma, prostatism,etc
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Low-dose amitriptyline; 25mg; to be taken by mouth, in capsule form, alternate days for 2 weeks, then daily administration; 3 month duration Bottles will be returned at the end of the study to assess compliance.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615000301561